BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/29/2024 8:40:08 AM | Browse: 138 | Download: 513
 |
Received |
|
2024-08-27 08:40 |
|
Peer-Review Started |
|
2024-09-05 02:15 |
|
First Decision by Editorial Office Director |
|
2024-10-11 03:37 |
|
Return for Revision |
|
2024-10-11 03:37 |
|
Revised |
|
2024-10-24 17:10 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-11-12 02:36 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-11-12 06:28 |
|
Articles in Press |
|
2024-11-12 06:28 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-11-15 00:54 |
|
Publish the Manuscript Online |
|
2024-11-29 08:40 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Anmol Singh, Aalam Sohal and Akash Batta |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Akash Batta, Assistant Professor, MD, Department of Cardiology, Dayanand Medical College and Hospital, Tagore Nagar, Civil Lines, Ludhiana 141001, Punjab, India. akashbatta02@gmail.com |
| Key Words |
Glucagon-like peptide-1 receptor agonists; Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction-associated steatohepatitis; Liver fibrosis; Semaglutide; Tirzepatide; Survodutide |
| Core Tip |
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1/3rd of the global population, leading to significant morbidity and mortality. GLP-1 agonists may decrease the risk of progression of MASLD by reducing fatty acid oxidation and cytokine production. GLP-1/GIP receptor agonists (RA) (tirzepatide) and Glucagon/GLP-1 RA (survodutide, efinopegdutide and pemvidutide), have also shown promising results in resolving metabolic dysfunction-associated steatohepatitis (MASH) and demonstrating histological improvement in liver fibrosis. The advancing field of MASH management points to a promising future, with combination therapies likely to significantly improve patient outcomes. |
| Publish Date |
2024-11-29 08:40 |
| Citation |
Singh A, Sohal A, Batta A. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J Gastroenterol 2024; 30(48): 5205-5211 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i48/5205.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i48.5205 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
